Orthopädie & Rheuma

, Volume 21, Issue 2, pp 39–43 | Cite as

Ziel ist die Vermeidung infektiöser Komplikationen

Perioperatives Management bei Gelenkeingriffen unter Immunsuppressiva

Fortbildung

Mangels kontrollierter Studien herrscht bezüglich des perioperativen Umgangs mit Immunsuppressiva große Unsicherheit. Das gilt auch für operative Eingriffe an Gelenken. Weitertherapie ohne Pause kann das postoperative Risiko für Infektionen und Wundheilungsstörungen erhöhen, zu langes Pausieren einen Schub der Grunderkrankung auslösen. Faktoren wie Aktivität der Grunderkrankung, Komorbiditäten, individuelle Infektanamnese und Art des Eingriffes modulieren das Risiko zusätzlich.

Literatur

  1. 1.
    Deutsches Rheuma-Forschungszentrum Berlin, Daten der Kerndokumentation 2015. Noch unpubliziertGoogle Scholar
  2. 2.
    Krüger K, Albrecht K, Rehart S et al (2014) Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur perioperativen Vorgehensweise unter Therapie mit DMARD und Biologicals bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 73:77–84 CrossRefPubMedCrossRefGoogle Scholar
  3. 3.
    Goodman SM, Springer B, Guyatt G et al (2017) American College of Rheumatology/American Association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheum. https://doi.org/10.1002/art.40149Google Scholar
  4. 4.
    Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293 CrossRefPubMedCrossRefGoogle Scholar
  5. 5.
    Doran MF, Crowson CS, Pond GR et al (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294–2300 CrossRefPubMedCrossRefGoogle Scholar
  6. 6.
    Bongartz T, Halligan CS, Osmon DR et al (2008) Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 59:1713–1720 CrossRefPubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Berbari EF, Osmon DR, Lahr B et al (2012) The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification. Infect Control Hosp Epidemiol 33:774–781 CrossRefPubMedCrossRefGoogle Scholar
  8. 8.
    George MD, Baker JF, Yenchin Hsu J et al (2017) Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty. Arthritis Care Res. https://doi.org/10.1002/acr.23209Google Scholar
  9. 9.
    Nikolaus OB, McLendon PB, Hanssen AD et al (2016) Factors associated with 20-year cumulative risk of infection after aseptic index revision total knee arthroplasty. J Arthroplasty 31:872–877 CrossRefPubMedCrossRefGoogle Scholar
  10. 10.
    Den Broeder AA, Creemers MC, Fransen J et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689–695PubMedGoogle Scholar
  11. 11.
    Bissar L, Almoallim H, Albazli K et al (2013) Perioperative management of patients with rheumatic diseases. Open Rheumatol J 7:42–50 CrossRefPubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53–61 CrossRefPubMedCrossRefGoogle Scholar
  13. 13.
    Somayaji R, Barnabe C, Martin L (2013) Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J 7:119–124 CrossRefPubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Marik PE, Varon J (2008) Requirement of perioperative stress doses of corticosteroids. A systematic review of the literature. Arch Surg 143:1222–1226 CrossRefPubMedCrossRefGoogle Scholar
  15. 15.
    Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60:214–217 CrossRefPubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Sany J, Anaya JM, Canovas F et al (1993) IInfluence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 20:1129–1132 PubMedPubMedGoogle Scholar
  17. 17.
    Visser K, Katchamart W, Loza E et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086–1093 CrossRefPubMedCrossRefGoogle Scholar
  18. 18.
    Loza E, Martinez-Lopez JA, Carmona L (2009) A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol 27:856–862 PubMedPubMedGoogle Scholar
  19. 19.
    Fuerst M, Möhl H, Baumgärtel K et al (2006) Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 26:1138–1142 CrossRefPubMedCrossRefGoogle Scholar
  20. 20.
    Rehart S, Petak N (2007) Moderne rheumatische Basistherapie perioperativ. Akt Rheumatol 32:74–77 CrossRefCrossRefGoogle Scholar
  21. 21.
    Tanaka N, Sakahashi H, Sato E et al (2003) Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 9:115–118 CrossRefPubMedCrossRefGoogle Scholar
  22. 22.
    Van Riel PLCM, Smolen JS, Emery P et al (2004) Leflunomide: a manageable safety profile. J Rheumatol 31(Suppl 71):21–24Google Scholar
  23. 23.
    da Cunha BM, da Mota MHL, Dos Santos-Neto LL et al (2012) Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy. Int J Rheumatol. https://doi.org/10.1155/2012/369565PubMedPubMedCentralGoogle Scholar
  24. 24.
    Goh L, Jewell T, Laversuch C, Samanta A (2012) Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 32:5–13 CrossRefPubMedCrossRefGoogle Scholar
  25. 25.
    Pieringer H, Danninger K, Tzaribachev N et al (2013) Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively? — A systematic literature review. Yonsei Med J 54:253–257 CrossRefPubMedCrossRefGoogle Scholar
  26. 26.
    Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53–61 CrossRefPubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Rheumatologisches PraxiszentrumMünchenDeutschland

Personalised recommendations